BRCAness in biliary tract cancer: a new prognostic and predictive biomarker?
Samir HachemYara KassisMaria Cr HachemJoseph ZoueinJoseph GhariosHampig R KouriePublished in: Biomarkers in medicine (2023)
Cholangiocarcinoma (CCA) is a rare malignancy with a very poor prognosis. Considering that most cases of CCA are diagnosed at a locally advanced stage and the standard of care for advanced CCA remains suboptimal, new prognostic and predictive biomarkers must be developed to improve the management and survival of patients diagnosed with CCA regardless of disease stage. According to recent studies, 20% of biliary tract cancers exhibit the BRCAness phenotype, meaning that these tumors do not have germline mutations in BRCA but share phenotypic traits with tumors that possess hereditary BRCA mutations. Therefore, screening for these mutations in CCA patients is beneficial to predict tumor sensitivity and response to DNA-damaging chemotherapy such as platinum agents.
Keyphrases
- end stage renal disease
- poor prognosis
- locally advanced
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- radiation therapy
- squamous cell carcinoma
- long non coding rna
- clinical trial
- gene expression
- genome wide
- neoadjuvant chemotherapy
- papillary thyroid
- pain management
- dna repair
- circulating tumor
- single molecule
- childhood cancer